
Astria Therapeutics (ATXS) Stock Forecast & Price Target
Astria Therapeutics (ATXS) Analyst Ratings
Bulls say
Astria Therapeutics Inc. is making significant strides with its product candidates STAR-0215 and STAR-0310, both of which demonstrate promising efficacy and safety profiles, particularly with STAR-0310 showing greater therapeutic potential compared to first-generation OX40 antibodies due to its well-tolerated treatment responses. The potential for STAR-0310 to improve quality of life by reducing treatment burden positions it favorably within the market, complemented by BioCryst's established commercial infrastructure, which is expected to enhance operational profitability following the anticipated launch of navenibart. With a substantial market opportunity and the strategic growth potential supported by the synergistic capabilities of the combined entities, Astria is poised for significant advancements as it continues to build its pipeline and leverage upcoming news flow.
Bears say
The financial outlook for Astria Therapeutics Inc is marked by significant risks stemming from potential failures in clinical trials, which could hinder the advancement of its product candidates, such as STAR-0215 and STAR-0310. Additionally, the company's ability to secure necessary funding for the development of its therapies remains uncertain, posing a challenge for continuous progress in their pipeline. Lastly, the removal of the price target and a downgrade to a neutral position underscore concerns regarding the overall valuation, aggravated by the threat of acquisition uncertainties and unmet clinical milestones.
This aggregate rating is based on analysts' research of Astria Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Astria Therapeutics (ATXS) Analyst Forecast & Price Prediction
Start investing in Astria Therapeutics (ATXS)
Order type
Buy in
Order amount
Est. shares
0 shares